CRNX - Crinetics Pharmaceuticals, Inc.

40.12
-0.560   -1.396%

Share volume: 987,213
Last Updated: 03-03-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$40.68
-0.56
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 2%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.38%
1 Month
-15.41%
3 Months
-15.39%
6 Months
17.14%
1 Year
17.79%
2 Year
-7.79%
Key data
Stock price
$40.12
P/E Ratio 
0.00
DAY RANGE
$39.03 - $40.90
EPS 
-$4.95
52 WEEK RANGE
$24.10 - $57.99
52 WEEK CHANGE
$18.17
MARKET CAP 
2.509 B
YIELD 
N/A
SHARES OUTSTANDING 
104.705 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
1.77
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$954,133
AVERAGE 30 VOLUME 
$1,016,314
Company detail
CEO: Scott R. Struthers
Region: US
Website: crinetics.com
Employees: 210
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Crinetics Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism.

Recent news